Prognostic Role of Pretreatment Prognostic Nutritional Index in Advanced Lung Cancer Patients Receiving First-Line Immunotherapy: A Meta-Analysis
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Higher pretreatment prognostic nutritional index (PNI) is linked to better survival in advanced lung cancer patients receiving immunotherapy. This nutritional marker predicts improved progression-free and overall survival, especially in non-small cell lung cancer.
Area Of Science
- Oncology
- Immunotherapy Research
- Clinical Nutrition
Background
- The prognostic nutritional index (PNI) reflects nutritional status and immune function.
- Predictive biomarkers are crucial for optimizing immunotherapy efficacy in advanced lung cancer.
Purpose Of The Study
- To investigate the association between pretreatment PNI and survival outcomes in advanced lung cancer patients undergoing first-line immunotherapy.
- To evaluate the predictive value of PNI in different lung cancer subtypes and treatment combinations.
Main Methods
- A systematic literature search was conducted across multiple databases up to July 17, 2023.
- Meta-analysis of ten studies involving 1291 patients was performed to combine hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS).
- Subgroup analyses were conducted based on pathological type (NSCLC vs. SCLC) and concurrent therapies.
Main Results
- Higher pretreatment PNI was significantly associated with improved PFS (HR=0.62) and OS (HR=0.52) in advanced lung cancer patients receiving immunotherapy.
- The predictive significance of PNI for PFS and OS was primarily observed in non-small cell lung cancer (NSCLC) patients.
- Combination with other therapies did not influence the prognostic role of PNI.
Conclusions
- Pretreatment PNI is a significant prognostic factor for survival in advanced NSCLC patients treated with first-line immunotherapy.
- Patients with lower pretreatment PNI exhibit poorer survival outcomes, highlighting its clinical utility.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...